Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Yu Compares Treatment Options for Prostate Cancer

August 4th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

Dr. Choyke on Which Patients Benefit From Active Surveillance in Prostate Cancer

August 3rd 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

Experts Explain Impact of LATITUDE Abiraterone Data in Prostate Cancer

August 3rd 2017

Jorge Garcia, MD, and Kim Chi, MD, share their insights on the LATITUDE trial in prostate cancer.

Dr. Feldman on Challenges Facing the Development of Biomarkers for Prostate Cancer

August 3rd 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.

Dr. Chi on Abiraterone Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

August 1st 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses a study investigating abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Agarwal on Candidates for Docetaxel Versus Abiraterone and Prednisone

August 1st 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses how to determine which patient with prostate cancer is a candidate for docetaxel versus abiraterone acetate (Zytiga) and prednisone.

Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

July 31st 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

Prostate Cancer: Advice for Oncologists on AR-V7 Testing

July 31st 2017

Experimental Strategies for AR-V7+ CRPC

July 31st 2017

Precision Medicine in mCRPC

July 31st 2017

Recent AR-V7 Data in Prostate Cancer

July 31st 2017

Prostate Cancer: Educating Physicians About AR-V7 Testing

July 31st 2017

Practical Implications of AR-V7 Testing in Prostate

July 31st 2017

Prostate Cancer: Validation of AR-V7 Testing

July 31st 2017

John's Hopkins AR-V7 Test in Prostate

July 31st 2017

Prostate Cancer: Epic Sciences AR-V7 Test

July 31st 2017

Detection of AR-V7 in Prostate Cancer

July 31st 2017

AR-V7 as a Predictive Marker in Prostate Cancer

July 31st 2017

Prostate Cancer: Discovery and Importance of AR-V7

July 31st 2017

The Biology of Prostate Cancer

July 31st 2017